Episode Details
Back to Episodes
Johnson & Johnson's Resilient Climb Amidst Regulatory Wins and Mixed Analyst Sentiment
Published 1 year, 1 month ago
Description
As of the latest available data, Johnson and Johnson's stock price has been steadily climbing, reaching around one hundred sixty-seven dollars and ninety-two cents per share. The trading volume has been notable, though it has been below the average volume in recent days. For instance, on a recent trading day, the volume was approximately six million shares, compared to an average of about nine million shares.
Recently, Johnson and Johnson reported strong fourth-quarter results, with a five-point-three percent increase in sales, reaching twenty-two billion five hundred million dollars. This growth was driven by significant advancements in their medical technology and pharmaceutical divisions. The company also provided guidance for the upcoming year, expecting operational sales to range between ninety billion nine hundred million dollars and ninety-one billion seven hundred million dollars.
In terms of analyst updates, Johnson and Johnson's stock has received a mix of ratings. Guggenheim reaffirmed a neutral rating, while Wells Fargo and Morgan Stanley reduced their price targets. However, Bank of America increased its target price to one hundred seventy-one dollars. Additionally, Wolfe Research initiated coverage with an outperform rating and a target price of one hundred ninety dollars.
Johnson and Johnson has been in the news for its recent regulatory approvals, such as the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its drug DARZALEX SC. The company's stock has shown resilience in recent months, outperforming the broader market despite some volatility. Overall, Johnson and Johnson remains a major player in the healthcare sector, with a strong market capitalization and a diverse portfolio of products.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
This episode includes AI-generated content.
Recently, Johnson and Johnson reported strong fourth-quarter results, with a five-point-three percent increase in sales, reaching twenty-two billion five hundred million dollars. This growth was driven by significant advancements in their medical technology and pharmaceutical divisions. The company also provided guidance for the upcoming year, expecting operational sales to range between ninety billion nine hundred million dollars and ninety-one billion seven hundred million dollars.
In terms of analyst updates, Johnson and Johnson's stock has received a mix of ratings. Guggenheim reaffirmed a neutral rating, while Wells Fargo and Morgan Stanley reduced their price targets. However, Bank of America increased its target price to one hundred seventy-one dollars. Additionally, Wolfe Research initiated coverage with an outperform rating and a target price of one hundred ninety dollars.
Johnson and Johnson has been in the news for its recent regulatory approvals, such as the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its drug DARZALEX SC. The company's stock has shown resilience in recent months, outperforming the broader market despite some volatility. Overall, Johnson and Johnson remains a major player in the healthcare sector, with a strong market capitalization and a diverse portfolio of products.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
This episode includes AI-generated content.